Maze Therapeutics, a US-based precision medicines developer co-founded by researchers from Harvard University, Stanford University and University of California, San Francisco, procured $190m in funding led by Matrix Capital Management yesterday.
General Catalyst, Andreesen Horowitz’s Bio+Health, Woodline Partners, Casdin Capital, City Hill Ventures, Foresite Capital, Driehaus Capital Management, Moore Strategic Ventures, Terra Magnum Capital Partners, NS Investments and unnamed others took part in the round.
Maze Therapeutics is working on treatments for genetically defined diseases with a high unmet need,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
